Imaging synaptic density in the living human brain
The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Synaptic density in the living human brain was measured with positron emission tomography and a synaptic vesicle glycoprotein 2A tracer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vivo imaging of synaptic density is now possible using PET and [ 11 C]UCB-J - a radioligand that binds to the synaptic vesicle protein 2A (SV2A) 41 .”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [41]
In the citing paper
“the most common method to quantify synaptic density has been the quantification of pre-(e.g., synaptophysin [9], synapsin [8]) and post-synaptic (e.g., PSD-95 [10]) genes/proteins”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
In the citing paper
“there was also good correlation between SV2A and the “gold standard” pre-synaptic density marker synaptophysin in western blot and confocal microscopy experiments”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“Thus, it was decided that SV2A can be used as an alternative to synaptophysin for quantification of synapse density”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [67]
In the citing paper
“quantification of radiotracer binding to SV2A does correlate with measures of synaptic vesicle number [8,9,69,70] and expression of other pre-synaptic proteins classically used in postmortem and in vitro work (e.g., synaptophysin, synapsin).”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [9]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Schizophrenia risk from complex variation of complement component 4
Sekar, A., Bialas, A. R., de Rivera, H., Davis, A., Hammond, T. R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al. (2016) · Nature · doi:10.1038/nature16549 · Cited by 2,394
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373 · cited 2×
“2 × 10(14) synapses per liter of brain tissue, as reported for the female human brain (42), and two to five SV2A copies per vesicle (31, 36), it can be estimated that there are 154 to 385 vesicles per synapse.”
BackgroundAzevedo, F. A. C., Carvalho, L. R. B., Grinberg, L. T., Farfel, J. M., Ferretti, R. E. L., Leite, R. E. P., Filho, W. J., Lent, R., & Herculano‐Houzel, S. (2009) · Journal of Comparative Neurology · doi:10.1002/cne.21974 · Cited by 2,337
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationDecreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636 · cited 1×
“Moreover, regional synaptic changes have been demonstrated in patients with autism (10), depression (11), or schizophrenia (12, 13).”
BackgroundWiedenmann, B., & Franke, W. W. (1985) · Cell · doi:10.1016/s0092-8674(85)80082-9 · Cited by 1,428 · cited 1×
“SYN is themost abundant synaptic vesicle protein (31) and is a widely used marker of synaptic density (32, 33), because it was one of the first characterized (29, 34) and cloned (35) vesicle membrane proteins.”
BackgroundLoss of mTOR-Dependent Macroautophagy Causes Autistic-like Synaptic Pruning Deficits
Tang, G., Gudsnuk, K., Kuo, S.-H., Cotrina, M. L., Rosoklija, G., Sosunov, A., Sonders, M. S., Kanter, E., Castagna, C., Yamamoto, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.07.040 · Cited by 1,146
Research works printed but not linked: 1
- 10.1097/01.wcb.0000033967.83623.34 · doi:10.1097/01.wcb.0000033967.83623.34 · Paper page
Cited by
Items 101–200 of 592
Potential neurobiological links between social isolation and Alzheimer's disease risk
Drinkwater, E., Davies, C., & Spires‐Jones, T. L. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15373 · Cited by 59
Mercier, J., Provins, L., & Valade, A. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.11.003 · Cited by 59
Self-citationPreliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder
D’Souza, D. C., Radhakrishnan, R., Naganawa, M., Ganesh, S., Nabulsi, N., Najafzadeh, S., Ropchan, J., Ranganathan, M., Cortes-Briones, J., Huang, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00891-4 · Cited by 55
Self-citationOnwordi, E. C., Whitehurst, T., Mansur, A., Statton, B., Berry, A., Quinlan, M., O’Regan, D. P., Rogdaki, M., Marques, T. R., Rabiner, E. A., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01515-3 · Cited by 55
Cai, Z., Li, S., Zhang, W., Pracitto, R., Wu, X., Baum, E., Finnema, S. J., Holden, D., Toyonaga, T., Lin, S.-F., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00618 · Cited by 54
Self-citationMolecular Imaging Approaches in Dementia
Villemagne, V. L., Barkhof, F., Garibotto, V., Landau, S. M., Nordberg, A., & van Berckel, B. N. M. (2021) · Radiology · doi:10.1148/radiol.2020200028 · Cited by 50
Validation and noninvasive kinetic modeling of [ 11 C]UCB-J PET imaging in mice
Bertoglio, D., Verhaeghe, J., Miranda, A., Kertesz, I., Cybulska, K., Korat, Š., Wyffels, L., Stroobants, S., Mrzljak, L., Dominguez, C., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19864081 · Cited by 54
“[(11)C]UCB-J appears the most promising due to its optimal pharmacokinetics and quantification properties as recently reported in both non-human primates(11) and healthy humans.(15,16) In addition, recent studies have demonstrated the feasibility of [(11)C]UCB-J PET in detecting pathological changes in synaptic densit…”
BackgroundPET Imaging for Early Detection of Alzheimer’s Disease
Bao, W., Jia, H., Finnema, S. J., Cai, Z., Carson, R. E., & Huang, Y. H. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.03.001 · Cited by 59
Self-citationYakoubi, R., Rollenhagen, A., von Lehe, M., Miller, D., Walkenfort, B., Hasenberg, M., Sätzler, K., & Lübke, J. H. (2019) · eLife · doi:10.7554/elife.48373 · Cited by 51
Late‐life physical activity relates to brain tissue synaptic integrity markers in older adults
Casaletto, K., Ramos‐Miguel, A., VandeBunte, A., Memel, M., Buchman, A., Bennett, D., & Honer, W. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12530 · Cited by 53
Synaptic Loss in Frontotemporal Dementia Revealed by [ 11 C ] UCB‐J Positron Emission Tomography
Malpetti, M., Jones, P. S., Cope, T. E., Holland, N., Naessens, M., Rouse, M. A., Rittman, T., Savulich, G., Whiteside, D. J., Street, D., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26543 · Cited by 53
“PET to quantify synapse density, where it is highly correlated with better established markers such as synaptophysin.(22) [(11)C]UCB-J therefore offers a bridge between preclinical and clinical models, where quantitative whole brain models of pathogenesis in dementia, including frontotemporal dementia, can be improved…”
MethodJohansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02285-8 · Cited by 53
“Here, we use the PET radioligand [ 11 C]UCB-J that binds to the Synaptic Vesicle glycoprotein 2A (SV2A), which enables visualization and quanti-fi cation of pre-synaptic density [16], as a proxy for synaptic plasticity.”
Nazeri, A., Schifani, C., Anderson, J. A. E., Ameis, S. H., & Voineskos, A. N. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.03.003 · Cited by 60
Synaptic Damage and Its Clinical Correlates in People With Early Huntington Disease: A PET Study
Delva, A., Michiels, L., Koole, M., Van Laere, K., & Vandenberghe, W. (2022) · Neurology · doi:10.1212/wnl.0000000000012969 · Cited by 51
“SV2A is ubiquitously present in presynaptic terminals throughout the brain.(15) The aim of the present study was to determine themagnitude and anatomic extent of synaptic damage and its clinical correlates in premanifest and early manifest HDmutation carriers.”
BackgroundMethodSimulation and assimilation of the digital human brain
Lu, W., Du, X., Wang, J., Zeng, L., Ye, L., Xiang, S., Zheng, Q., Zhang, J., Xu, N., Feng, J., et al. (2024) · Nature Computational Science · doi:10.1038/s43588-024-00731-3 · Cited by 68
Dementia spectrum disorders: lessons learnt from decades with PET research
Wilson, H., Pagano, G., & Politis, M. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-01975-4 · Cited by 47
Synaptic Loss in Multiple Sclerosis: A Systematic Review of Human Post-mortem Studies
Möck, E. E. A., Honkonen, E., & Airas, L. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.782599 · Cited by 53
“neurological and psychiatric diseases, such as Parkinson’s, dementia with Lewy bodies (59, 60), Alzheimer’s disease (61–63), temporal lobe epilepsy (58, 64), major depressive disorder (65), post-traumatic stress disorder (65), and schizophrenia (66).”
BackgroundMethodLi, X., You, C., Yang, Y., Yang, Y., Li, P., Gu, G., Chung, L. W., Lv, H., & Zhang, X. (2018) · Chemical Science · doi:10.1039/c7sc04639a · Cited by 49
Data-Driven Motion Detection and Event-by-Event Correction for Brain PET: Comparison with Vicra
Lu, Y., Naganawa, M., Toyonaga, T., Gallezot, J., Fontaine, K. M., Ren, S., Revilla, E. M., Mulnix, T., & Carson, R. E. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.235515 · Cited by 49
“These included 13 with 18F-FDG (injected activity, 184 6 4 MBq) and 10 with 11C-UCB-J (363 6 178 MBq), a novel radiotracer that binds to the synaptic vesicle glycoprotein 2A (15), which has shown its potential as a synaptic density marker in Alzheimer disease (16).”
BackgroundMethodSelf-citationHanson, J. L., & Nacewicz, B. M. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.624705 · Cited by 45
“Complementing this, the novel PET tracer UCB-J binds the synaptic marker SV2A as a direct, albeit relative, measure of synapse density (Finnema et al., 2016).”
BackgroundHermanides, J., Hong, Y. T., Trivedi, M., Outtrim, J. G., Aigbirhio, F. I., Nestor, P. J., Guilfoyle, M. R., Winzeck, S., Newcombe, V., Das, T., et al. (2021) · Brain · doi:10.1093/brain/awab255 · Cited by 50
Vanderlinden, G., Ceccarini, J., Vande Casteele, T., Michiels, L., Lemmens, R., Triau, E., Serdons, K., Tournoy, J., Koole, M., Vandenbulcke, M., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01672-x · Cited by 47
“Furthermore, a number of radiopharmaceuticals have been developed that target synaptic vesicle glycoprotein 2 A (SV2A), which is ubiquitously expressed in presynaptic vesicle membranes [22], thus providing a quantitative valid proxy for synaptic density [23].”
BackgroundSynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes, S. E., Honhar, P., Tinaz, S., Naganawa, M., Hilmer, A. T., Gallezot, J., Dias, M., Yang, Y., Toyonaga, T., Esterlis, I., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00655-9 · Cited by 55
“We can image synapses in the living brain with positron emission tomography (PET) and the radioligand [ 11 C] UCB-J, which binds to the synaptic vesicle glycoprotein 2A (SV2A) – a protein ubiquitously expressed on all synaptic vesicles that is used as a marker of synaptic density 4 .”
MethodSelf-citationQuantitative Rodent Brain Receptor Imaging
Herfert, K., Mannheim, J. G., Kuebler, L., Marciano, S., Amend, M., Parl, C., Napieczyńska, H., Maier, F. M., Vega, S. C., & Pichler, B. J. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01368-9 · Cited by 48
Wang, J., Huang, Q., Chen, X., You, Z., He, K., Guo, Q., Huang, Y. H., Yang, Y., Lin, Z., Guo, T., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02501-z · Cited by 49
“In participants with aMCI, global A β deposition was negatively associated with hippocampal SV2A binding and higher [ 18 F]MK6240 binding was related to lower [ 11 C]UCB-J binding in the medial temporal lobe [14, 15].”
Self-citationKinetics and 28-day test–retest repeatability and reproducibility of [ 11 C]UCB-J PET brain imaging
Tuncel, H., Boellaard, R., Coomans, E. M., de Vries, E. F., Glaudemans, A. W., Feltes, P. K., García, D. V., Verfaillie, S. C., Wolters, E. E., Sweeney, S. P., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20964248 · Cited by 45
“The first-in-human [(11)C]UCB-J positron emission tomography (PET) study showed comparable results.(11) Quantification of specific binding of [(11)C]UCB-J with a validated tracer kinetic model is crucial in clinical studies not only for identification of early synaptic pathology in cross-sectional studies but also for…”
Luan, Y., Wang, W., Huang, Q., Wang, Y., Nussbaumer, J., Wang, J., Steward, A., Roemer, S. N., Guan, Y., Ewers, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61497-4 · Cited by 51
Current radiotracers to image neurodegenerative diseases
Tiepolt, S., Patt, M., Aghakhanyan, G., Meyer, P., Hesse, S., Barthel, H., & Sabri, O. (2019) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-019-0070-7 · Cited by 51
Smart, K., Liu, H., Matuskey, D., Chen, M.-K., Torres, K., Nabulsi, N., Labaree, D., Ropchan, J., Hillmer, A. T., Huang, Y., et al. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20946198 · Cited by 42
“UCB-J, which binds to the synaptic vesicle glycoprotein 2A (SV2A).(1) Despite a growing body of literature demonstrating the utility of [(11)C]UCB-J to assess synaptic loss or dysfunction in clinical populations,”
BackgroundResultSelf-citationNeuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D. J., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 46
“…at a cellular/molecular level, the use of recently characterised PET ligands focusing on the synaptic glycoprotein 2A (SV2A, a marker of pre-synaptic terminals; [11C]UCB-J) and mitochondrial complex 1 (MC1, a marker of mitochondrial density; [18F]BCPP-EF) offer promising prospects [74 – 76].”
BackgroundMolecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study
Holland, N., Malpetti, M., Rittman, T., Mak, E. E., Passamonti, L., Kaalund, S. S., Hezemans, F. H., Jones, P. S., Savulich, G., Hong, Y. T., et al. (2022) · Brain · doi:10.1093/brain/awab282 · Cited by 39
“a common binding target with (11)C-UCB-J, which has a high specificity for SV2A in previous in vivo and in vitro validation studies.(38,71) Third, we note that in PET studies of neurodegeneration with atrophy, grey matter volume loss can affect the interpretation of PET signals.”
The study of noninvasive brain stimulation using molecular brain imaging: A systematic review
Tremblay, S., Tuominen, L. J., Zayed, V. K., Pascual‐Leone, Á., & Joutsa, J. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117023 · Cited by 40
PET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
In vivo coupling of dendritic complexity with presynaptic density in primary tauopathies
Mak, E., Holland, N., Jones, P. S., Savulich, G., Low, A., Malpetti, M., Kaalund, S. S., Passamonti, L., Rittman, T., Romero-Garcia, R., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.016 · Cited by 36
Angarita, G. A., Worhunsky, P. D., Naganawa, M., Toyonaga, T., Nabulsi, N. B., Li, C. R., Esterlis, I., Skosnik, P. D., Radhakrishnan, R., Pittman, B., et al. (2022) · Addiction Biology · doi:10.1111/adb.13123 · Cited by 38
“In vivo measures of (11)C-UCB-J volume of distribution (VT) have been positively correlated with ex vivo measures of densities of both SV2A and synaptophysin (a ‘gold-standard’ vesicular marker of synaptic number in vitro).(28) Our group has demonstrated the tracer's superior imaging properties, test–retest reproducib…”
Self-citationThomsen, M. B., Jacobsen, J., Lillethorup, T. P., Schacht, A. C., Simonsen, M., Romero-Ramos, M., Brooks, D. J., & Landau, A. M. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20931140 · Cited by 38
“A unilateral reduction of [11C] UCB-J binding was found at the seizure onset zone in the hippocampus of 3 patients with temporal lobe epilepsy.(8) In 10 Alzheimer’s disease patients, a significant reduction in hippocampal [11C]UCB-J binding was seen compared to 11 cognitively healthy controls.”
Dendritic Polyglycerol Sulfates in the Prevention of Synaptic Loss and Mechanism of Action on Glia
Maysinger, D., Ji, J. X., Moquin, A., Hossain, S., Hancock, M. A., Zhang, I., Chang, P. K. ‐., Rigby, M., Anthonisen, M., Grütter, P., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00301 · Cited by 39
SV2A PET imaging in human neurodegenerative diseases
Bavarsad, M. S., & Grinberg, L. T. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380561 · Cited by 39
Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy
Bagnato, F. R., Gauthier, S. A., Laule, C., Moore, G. R. W., Bove, R. M., Cai, Z., Cohen‐Adad, J., Harrison, D. M., Klawiter, E. C., Morrow, S. A., et al. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12700 · Cited by 44
Aceves-Serrano, L., Neva, J. L., & Doudet, D. J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.787403 · Cited by 42
“SV2A radiotracers such as [11C]UCB-J and [18F]UCBH are capable of quantifying SV2A density in healthy participants (Finnema et al., 2016; Bahri et al., 2017) and patient populations (Bastin et al., 2020; Holland et al., 2020).”
BackgroundInfluentialOnwordi, E. C., Whitehurst, T., Shatalina, E., Mansur, A., Arumuham, A., Osugo, M., Marques, T. R., Jauhar, S., Gupta, S., Mehrotra, R., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.05.022 · Cited by 39
“Regional distribution volume ratio (DVR) was obtained using the CS as a pseudoreference region (11,18), thus deriving DVR as a ratio of ROI V T to CS V T .”
BackgroundMethodInfluentialTracing synaptic loss in Alzheimer's brain with SV2A PET‐tracer UCB‐J
Kumar, A., Scarpa, M., & Nordberg, A. K. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13720 · Cited by 37
Cognitive synaptopathy: synaptic and dendritic spine dysfunction in age-related cognitive disorders
Barrantes, F. J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1476909 · Cited by 41
“…glycoprotein 2A in the form of a novel PET radioligand, 11 C-UCB-J, this biomarker was used to quantify synaptic density in the living human brain (Finnema et al., 2016) and to compare amyloid-positive patients exhibiting either MCI or AD dementia with amyloid-negative aged-matched controls (Chen…”
van Aalst, J., Ceccarini, J., Sunaert, S. G., Dupont, P. J., Koole, M. J. B., & Laere, K. V. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20981502 · Cited by 39
“The latter is highly correlated with SV2A in terms of cellular and brain distribution.(11) These findings also show that resting-state glucose consumption can be considered as coupled to excitatory (glutamatergic) and inhibitory (GABA-ergic) synaptic activity as this can be considered the main determinant of brain ene…”
BackgroundResultExercise protects synaptic density in a rat model of Parkinson's disease
Binda, K. H., Lillethorup, T. P., Real, C. C., Bærentzen, S. L., Nielsen, M. N., Orlowski, D., Brooks, D. J., Chacur, M., & Landau, A. M. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113741 · Cited by 35
Partial volume correction analysis for 11C-UCB-J PET studies of Alzheimer's disease
Lu, Y., Toyonaga, T., Naganawa, M., Gallezot, J.-D., Chen, M.-K., Mecca, A. P., van Dyck, C. H., & Carson, R. E. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118248 · Cited by 37
“The participants underwent 11C-UCB-J (Finnema et al., 2016) (550±208 MBq) PET dynamic studies on the HRRT (de Jong et al.”
InfluentialSelf-citationDelva, A., Laere, K. V., & Vandenberghe, W. (2022) · Movement Disorders · doi:10.1002/mds.29148 · Cited by 37
“(11)C-UCB-J targets synaptic vesicle protein 2A (SV2A), which is ubiquitously present in presynaptic terminals throughout the brain, irrespective of neurotransmitter type.(20) As such, (11)C-UCB-J is also sensitive to synaptic damage in non-dopaminergic circuits, which could underlie some of the non-motor symptoms of…”
BackgroundReductions in synaptic marker SV2A in early-course Schizophrenia
Yoon, J. H., Zhang, Z., Mormino, E. C., Davidzon, G., Minzenberg, M., Ballon, J. S., Kalinowski, A., Hardy, K. V., Naganawa, M., Carson, R. E., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.02.026 · Cited by 37
Self-citationA translational perspective on the anti-anhedonic effect of ketamine and its neural underpinnings
Pulcu, E., Guinea, C., Cowen, P. J., Murphy, S. E., & Harmer, C. J. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01183-1 · Cited by 35
Luppi, A. I., Golkowski, D., Ranft, A., Ilg, R., Jordan, D., Bzdok, D., Owen, A. M., Naçi, L., Stamatakis, E. A., Amico, E., et al. (2025) · Nature Human Behaviour · doi:10.1038/s41562-025-02121-9 · Cited by 44
“This may be attributed to the fact that transmodal association cortices have the longest maturation times in the human brain and the highest levels of synaptic plasticity and turnover 34,59,60 .”
The Rise of Synaptic Density PET Imaging
Becker, G., Dammicco, S., Bahri, M. A., & Salmon, E. (2020) · Molecules · doi:10.3390/molecules25102303 · Cited by 31
“UCB-J in vivo quantification in human brain was presented in the publication of Finnema 2016 where the authors proposed the CS as a reference region for non-displaceable binding [40].”
BackgroundMethodLooking Back at the Next 40 Years of ASD Neuroscience Research
McPartland, J. C., Lerner, M. D., Bhat, A. N., Clarkson, T., Jack, A., Koohsari, S., Matuskey, D., McQuaid, G. A., Su, W.-C., & Trevisan, D. A. (2021) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-021-05095-5 · Cited by 39
Self-citationPositron emission tomography imaging in evaluation of MS pathology in vivo
Högel, H., Rissanen, E., Vuorimaa, A., & Airas, L. M. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518791680 · Cited by 36
Synaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34
“…a baboon study investigating both synaptophysin immunolabelling and [ 11 C]UCB-J V T showed a very close correlation between V T and synaptophysin immuno fl uorescence [47], providing cross-validation between the PET measure and one of the most widely used ex vivo synaptic markers (Fig.”
BackgroundZheng, C., Holden, D., Zheng, M.-Q., Pracitto, R., Wilcox, K. C., Lindemann, M., Felchner, Z., Zhang, L., Tong, J., Fowles, K., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05597-5 · Cited by 35
“clinical development of new drug candidates targeting SV2A, and to measure changes of SV2A in neuropsychiatric diseases [5-10].”
InfluentialSelf-citationLeung, E., Lau, E. W., Liang, A., de Dios, C., Suchting, R., Östlundh, L., Masdeu, J. C., Fujita, M., Sanches, M., Soares, J. C., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01410-9 · Cited by 36
“SV2A has a high degree of correlation with synaptophysin in baboons [89], suggesting that SV2A alterations may parallel synaptophysin levels in a region-specific manner.”
BackgroundBrekk, O. R., Moskites, A., Isacson, O., & Hallett, P. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-33474-z · Cited by 34
Patel, S., Knight, A. C., Krause, S., Teceno, T. J., Tresse, C., Li, S., Cai, Z., Gouasmat, A., Carroll, V. M., Barret, O., et al. (2019) · Molecular Imaging and Biology · doi:10.1007/s11307-019-01428-0 · Cited by 33
Self-citationHalogen-containing semiconductors: From artificial photosynthesis to unconventional computing
Klejna, S., Mazur, T., Wlaźlak, E., Zawal, P., Soo, H. S., & Szacilowski, K. T. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213316 · Cited by 34
Clinical application of AI-based PET images in oncological patients
Dai, J., Wang, H., Xu, Y., Chen, X., & Tian, R. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.03.005 · Cited by 35
Cervenka, S., Frick, A., Bodén, R., & Lubberink, M. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01990-2 · Cited by 32
“The PET radioligand [(11)C]UCB-J binds to the synaptic vesicle glycoprotein 2A (SV2A), which has shown high correspondence to the established post-mortem marker synaptophysin in non-human primate studies [31].”
BackgroundWeiss, J. J., Calvi, R. M., Naganawa, M., Toyonaga, T., Farhadian, S., Chintanaphol, M., Chiarella, J., Zheng, M., Ropchan, J. R., Huang, Y. H., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab484 · Cited by 32
“SV2A concentration measured by high-resolution positron emission tomography (PET) imaging effectively reflects the density of nerve terminals, and therefore synaptic density, and has been validated as a measure of synaptic density in prior studies [19].”
BackgroundSelf-citationPrevention of epilepsy: Should we be avoiding clinical trials?
Klein, P., & Tyrlíková, I. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.05.024 · Cited by 33
“Targeted protein analyses with good preliminary data include inflammatory cytokines such as IL-1 b [83] and the inflammation regulation protein, high mobility group box-1 (HMGB1) (Annamaria Vezzani, personal communication).”
BackgroundQuantification of SV2A Binding in Rodent Brain Using [18F]SynVesT-1 and PET Imaging
Sadasivam, P., Fang, X. T., Toyonaga, T., Lee, S., Xu, Y., Zheng, M.-Q., Spurrier, J., Huang, Y., Strittmatter, S. M., Carson, R. E., et al. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01567-9 · Cited by 31
Self-citationPharmacokinetic Characterization of [18F]UCB-H PET Radiopharmaceutical in the Rat Brain
Becker, G., Warnier, C., Serrano, M. E., Bahri, M. A., Mercier, J., Lemaire, C., Salmon, E., Luxen, A., & Plenevaux, A. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00235 · Cited by 31
Self-citationChanges in synaptic density in the subacute phase after ischemic stroke: A 11C-UCB-J PET/MR study
Michiels, L., Mertens, N., Thijs, L., Radwan, A., Sunaert, S., Vandenbulcke, M., Verheyden, G., Koole, M., Van Laere, K., & Lemmens, R. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211047759 · Cited by 27
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Luppi, A. I., Girn, M., Rosas, F. E., Timmermann, C., Roseman, L., Erritzøe, D., Nutt, D. J., Stamatakis, E. A., Spreng, R. N., Xing, L., et al. (2023) · Brain · doi:10.1093/brain/awad311 · Cited by 35
“96,97 Thus, at the top of the cortical hierarchy we find that (i) synapse formation is least inhibited by myelination; (ii) there is transcription of genes supporting synapse turnover; (iii) aerobic glycolysis makes continuously available the kind of biosynthetic materials that would support…”
What is the experience of men and women with congestive heart failure?
Costello, J. F., & Boblin, S. L. (2004) · PubMed · Cited by 45
Identifying brain networks in synaptic density PET (11C-UCB-J) with independent component analysis
Fang, X. T., Toyonaga, T., Hillmer, A. T., Matuskey, D., Holmes, S. E., Radhakrishnan, R., Mecca, A. P., van Dyck, C. H., D'Souza, D. C., Esterlis, I., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118167 · Cited by 30
Self-citationBertoglio, D., Verhaeghe, J., Wyffels, L., Miranda, A., Stroobants, S., Mrzljak, L., Dominguez, C., Skinbjerg, M., Bard, J., Liu, L., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262709 · Cited by 30
“Since the development of SV2A radioligands for in vivo imaging of SV2A (18,19), preclinical and clinical investigations have been restricted on the brain despite SV2A is distributed in all grey matter, including the spinal cord (33).”
BackgroundSimplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort
Naganawa, M., Gallezot, J.-D., Finnema, S. J., Matuskey, D., Mecca, A., Nabulsi, N. B., Labaree, D., Ropchan, J., Malison, R. T., D’Souza, D. C., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.243949 · Cited by 28
“The centrum semiovale was used as the reference region (1).”
BackgroundMethodSelf-citationAndersen, K. B., Hansen, A. K., Schacht, A. C., Horsager, J., Gottrup, H., Klit, H., Danielsen, E. H., Poston, K. L., Pavese, N., Brooks, D. J., et al. (2023) · Movement Disorders · doi:10.1002/mds.29375 · Cited by 30
“The novel PET tracer [(11)C]UCB-J binds to the presynaptic vesicle protein SV2A and was in 2017 validated as the first in vivo universal synaptic density marker in humans, after confirmation of an excellent linear correlation between SV2A and the “gold standard” synaptic marker synaptophysin.(7-9) SV2A is ubiquitously…”
BackgroundApplication of biomarker-derived fluorescent probes for the detection of Alzheimer's disease
Ding, H., Li, Z., Luo, K., Gong, Q., & Tian, X. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117369 · Cited by 31
van Dyck, C. H., Mecca, A. P., O’Dell, R. S., Bartlett, H. H., Diepenbrock, N. G., Huang, Y., Hamby, M. E., Grundman, M., Catalano, S. M., Caggiano, A. O., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01382-2 · Cited by 29
“[ 11 C]UCB-J was recently developed as a PET tracer for SV2A and advanced for human studies [13].”
MethodSelf-citationQuantitative PET Imaging in Drug Development: Estimation of Target Occupancy
Naganawa, M., Gallezot, J., Rossano, S. M., & Carson, R. E. (2017) · Bulletin of Mathematical Biology · doi:10.1007/s11538-017-0374-2 · Cited by 30
Self-citationBertoglio, D., Zajicek, F., Lombaerde, S. D., Miranda, A., Stroobants, S., Wang, Y., Dominguez, C., Munoz-Sanjuan, I., Bard, J., Liu, L., et al. (2022) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x221101648 · Cited by 29
“Among the developed SV2A radioligands, [(11)C]UCB-J displayed optimal pharmacokinetics and quantification properties for measuring synaptic density in humans.(9,10) Additionally, it was demonstrated to offer an excellent clinical marker for the measurement of synaptic alterations in a variety of brain disorders, inclu…”
MethodLeveraging ultra-high field (7T) MRI in psychiatric research
Calabro, F. J., Parr, A. C., Sydnor, V. J., Hetherington, H. P., Prasad, K. M. R., Ibrahim, T. S., Sarpal, D. K., Famalette, A., Verma, P., & Luna, B. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01980-6 · Cited by 33
Bavarsad, M. S., Spina, S., Oehler, A., Allen, I. E., Suemoto, C. K., Leite, R. E. P., Seeley, W. S., Green, A., Jagust, W., Rabinovici, G. D., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02816-9 · Cited by 31
In vivo Detection of Alzheimer's Disease.
Leuzy, A., Heurling, K., Ashton, N. J., Schöll, M., & Zimmer, E. R. (2018) · Europe PMC (PubMed Central) · Cited by 42
Pazarlar, B. A., Aripaka, S. S., Petukhov, V., Pinborg, L. H., Khodosevich, K., & Mikkelsen, J. D. (2022) · Molecular Brain · doi:10.1186/s13041-022-00931-w · Cited by 31
“Previously, decreased SV2A binding has been reported only in the hippocampus and amygdala, probably due to sclerosis pathology in medically refractory TLE patients [14, 26].”
BackgroundVisser, M., O’Brien, J. T., & Mak, E. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102197 · Cited by 28
“Utilising SV2A PET imaging as a potential indicator of synaptopa-thology, researchers can gain insights into the dynamics of synaptic density, revealing patterns of abnormality (Finnema et al., 2016; Fin-nema et al., 2020; Rizzoli and Betz, 2005).”
BackgroundInfluentialToyonaga, T., Khattar, N., Wu, Y., Lu, Y., Naganawa, M., Gallezot, J., Matuskey, D., Mecca, A. P., Pittman, B. P., Dias, M., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06487-8 · Cited by 29
“Centrum semiovale (CS) has been used as a reference region for [ 11 C]UCB-J PET [7, 12, 25, 38] with minimal specific binding; this region has been proposed to measure the non-displaceable distribution volume ( V ND ).”
Self-citationDifferential effects of neurodegeneration biomarkers on subclinical cognitive decline
Merluzzi, A. P., Vogt, N. M., Norton, D., Jonaitis, E. M., Clark, L. R., Carlsson, C. M., Johnson, S. C., Asthana, S., Blennow, K., Zetterberg, H., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.004 · Cited by 29
“[(18)F] fluorodeoxyglucose positron emission tomography and structural magnetic resonance imaging are common methods of indexing neurodegenerative processes [2], and additional sensitive brain imaging metrics are undergoing testing and development—including synaptic vesicle glycoprotein 2A for indexing synaptic densit…”
MethodWang, R., Liu, H., Toyonaga, T., Shi, L., Wu, J., Onofrey, J. A., Tsai, Y., Naganawa, M., Ma, T., Liu, Y., et al. (2021) · Medical Physics · doi:10.1002/mp.15073 · Cited by 30
Self-citationLower synaptic density is associated with psychiatric and cognitive alterations in obesity
Asch, R., Holmes, S. E., Jastreboff, A. M., Potenza, M. N., Baldassarri, S. R., Carson, R. E., Pietrzak, R. H., & Esterlis, I. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01111-5 · Cited by 31
“Using positron emission tomography (PET) to measure [(11)C]UCB-J binding to SV2A provides a method for estimating synaptic vesicle density and can serve as a surrogate for presynaptic terminal density in vivo [33].”
MethodSelf-citationГудашева, Т. А., Таллерова, А. В., Межлумян, А. Г., Антипова, Т. А., Логвинов, И. О., Firsova, Y. N., Povarnina, P. Y., & Середенин, С. Б. (2021) · Biomolecules · doi:10.3390/biom11020252 · Cited by 29
“inversely with the synapses density in the prefrontal cortex and hippocampus [29], while the synapses density correlates with the synaptophysin level [30].”
BackgroundMuglia, P., Hannestad, J. O., Brandt, C., DeBruyn, S., Germani, M., Lacroix, B. D., Majoie, M., Otoul, C., Sciberras, D. G., Steinhoff, B. J., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa183 · Cited by 28
Self-citationPET Imaging in Animal Models of Alzheimer’s Disease
Chen, B., Marquez-Nostra, B. V., Belitzky, E., Toyonaga, T., Tong, J., Huang, Y. H., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.872509 · Cited by 32
Self-citationA 3D atlas of functional human brain energetic connectome based on neuropil distribution
Yu, Y., Akif, A., Hermán, P., Cao, M., Rothman, D. L., Carson, R. E., Agarwal, D., Evans, A. C., & Hyder, F. (2022) · Cerebral Cortex · doi:10.1093/cercor/bhac322 · Cited by 31
Self-citation3D synaptic organization of layer III of the human anterior cingulate and temporopolar cortex
Cano-Astorga, N., Plaza-Alonso, S., DeFelipe, J., & Alonso-Nanclares, L. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad232 · Cited by 26
Holland, N., Jones, P. S., Savulich, G., Naessens, M., Malpetti, M., Whiteside, D. J., Street, D., Swann, P., Hong, Y. T., Fryer, T. D., et al. (2023) · Movement Disorders · doi:10.1002/mds.29421 · Cited by 26
“We used [(11)C]UCB-J PET, which targets presynaptic vesicle glycoprotein SV2A, to estimate synaptic density in vivo.(26) Using this PET radioligand, we recently reported a widespread baseline in vivo synaptic loss (up to 30%) in a smaller cross-sectional cohort of patients with PSP and CBD.”
MethodLongitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease
Delva, A., Laere, K. V., & Vandenberghe, W. (2023) · Movement Disorders · doi:10.1002/mds.29501 · Cited by 26
“Centrum semiovale may also not be the perfect reference region because displacement studies with levetiracetam suggested a small amount of specific (11)C-UCB-J binding in this region.(38,39) In addition, the use of a MI4 20 cm field of view (FOV) silicon photomultiplier PET-computed tomography (CT) for (11)CUCB-J and…”
MethodWang, J., Huang, Q., He, K., Li, J., Guo, T., Yang, Y., Lin, Z., Li, S., Vanderlinden, G., Huang, Y. H., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13817 · Cited by 26
Self-citationRolandi, E., Cavedo, E., Pievani, M., Galluzzi, S., Ribaldi, F., Buckley, C. J., Cunningham, C. M., Guerra, U. P., Musarra, M., Morzenti, S., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.020 · Cited by 26
“, 2015), and [11C]UCB-J PET to assess the synaptic density of alternative brain pathways involved in POD, such as the fronto-limbic pathway (Finnema et al., 2016).”
MethodAutoradiographic mapping of synaptic vesicle glycoprotein 2A in non‐human primate and human brain
Varnäs, K., Stepanov, V., & Halldin, C. (2020) · Synapse · doi:10.1002/syn.22157 · Cited by 25
Sim, J. H., & Song, C. E. (2017) · Angewandte Chemie · doi:10.1002/ange.201611466 · Cited by 25
Healthy brain aging assessed with [18F]FDG and [11C]UCB-J PET
Andersen, K. B., Hansen, A. K., Knudsen, K., Schacht, A. C., Damholdt, M. F., Brooks, D. J., & Borghammer, P. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.06.007 · Cited by 27
Perani, D., Iaccarino, L., Lammertsma, A. A., Windhorst, A. D., Edison, P., Boellaard, R., Hansson, O., Nordberg, A. K., Jacobs, A. H., & IMBI Project (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.004 · Cited by 27
“Among the latter, another exciting and breakthrough molecular imaging approach currently under validation is the in vivo investigation of synaptic density using newly developed ad hoc tracers [231].”
BackgroundMethodInfluentialXiong, M., Roshanbin, S., Rokka, J., Schlein, E., Ingelsson, M., Sehlin, D., Eriksson, J., & Syvänen, S. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118302 · Cited by 24
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 29
“Direct assessment—via positron emission tomography of molecular targets in the neurotrophic cascade 79,80 or changes in synaptic density 81–85 —may be possible within the next few years.”
Metadata
- Authors
- Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., Spencer, D. D., Mercier, J., Hannestad, J., Huang, Y., & Carson, R. E.
- Affiliations
- Yale University (US)
- UCB Pharma (Belgium) (BE)
- Corresponding author
- Finnema, Sjoerd J.
- Hannestad, Jonas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-07-20
- Volume
- 8
- Issue
- 348
- Pages
- 348ra96-348ra96
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2503767557
- Cited by
- 575
- References
- 59
- Citations by year
- 2026: 52 · 2025: 70 · 2024: 81 · 2023: 54 · 2022: 92 · 2021: 67 · 2020: 54 · 2019: 43 · 2018: 23 · 2017: 31 · 2016: 6
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Swebilius Foundation
- UCB Pharma
- Swedish Research Council
- National Center for Advancing Translational Science (UL1 TR000142)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- synaptic density, SV2A, positron emission tomography, presynaptic terminals, synaptophysin, temporal lobe epilepsy, synaptic loss, Alzheimer's disease, neuroimaging
- MeSH terms
- Adult, Aged, Brain, Epilepsy, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Nerve Tissue Proteins, Synapses, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.